Public health officials need to focus on conserving the use of anti-microbial medicines amid the rapidly increasing incidence of drug-resistant infections, write two experts in medical policy. They propose that developers of such treatments be compensated based on the real value that products bring to society. They also note that research funding must increase to spur the development of better antibiotics.

Related Summaries